Where the Days Go: Time to Reimbursement in Greece, Stage by Stage

Speed to patients in Greece is shaped by a sequence of steps, not one decision. Published analysis of the national process shows where time is actually spent, and the largest share is not where many companies expect.

What the published data show

A peer-reviewed review of the Greek HTA process covered applications from July 2018 to February 2023. For new active substances, excluding orphan medicines, on the February 2023 positive list, the median time from marketing authorisation to HTA application was about 420 days. From application to reimbursement listing it was about 228 days. The study identifies the long gap before submission as the main driver of delay. These are historical medians from a defined period and may have changed since.

The stages inside the process

The assessment route has distinct stages, each with its own timing.

  • Clinical assessment by the HTA Committee, a median of about 114 days in the study.
  • Price negotiation by the Negotiation Committee, a median of about 60 days.
  • Ministerial decision and listing, roughly 42 days combined in the study across the final steps.
  • Statutory limit: the Ministry of Health is required to decide within 180 days of submission.

For orphan medicines the same study reported about 417 days from application to listing.

The controllable part

The pre-submission gap is largely within the company’s control. Reasons for delay can include launch sequencing decisions, dossier preparation, pricing considerations in other markets, and unresolved internal approvals. Because European reference pricing links markets, a company may deliberately hold back one launch to protect another price, but that should be a conscious decision with a documented trade-off, not a drift.

Shortening your own timeline

Start dossier preparation before marketing authorisation is granted, align the standardised submission with the evidence already prepared for the centralised procedure, and agree internally on price and discount parameters before negotiation opens. Where patients have urgent needs, consider whether an early access route is appropriate while reimbursement proceeds.

Reading the numbers with care

Medians describe the typical case, not every case. Some products moved much faster, particularly where the dossier was ready at the time of authorisation, and others waited far longer. The study also covers a particular period, during which the HTA system was still building capacity and reducing a backlog, so current timings should be checked against recent experience and official announcements.

The more useful reading is structural. Reimbursement involves several bodies and sequential steps, so the order in which work is done matters. Companies that treat the national submission as a project with its own plan, owner and deadlines, starting well before approval, tend to avoid the longest delays. Where a product addresses a serious unmet need, it is also worth reviewing the early access arrangements that operate alongside the standard route.

How PQRA helps

PQRA can help structure a Greek access timeline from the marketing authorisation onwards, prepare the standardised HTA submission, and coordinate regulatory, pricing and reimbursement steps so they run in parallel instead of in sequence.

To plan your Greek reimbursement timeline, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *